Recent Updates — LXEO
On September 29, 2026, Lexeo Therapeutics completed its acquisition of Mantle Therapeutics via a merger with a wholly-owned subsidiary. The transaction consideration included an aggregate upfront payment of $5.3 million in cash and $3 million in Lexeo common stock for outstanding Mantle shares. Additional contingent payments include a potential one-time cash payment of $1 million and up to $12 million in milestone payments over 12 years, payable in cash or equity based on development and regulatory achievements. Lexeo Therapeutics operates in the biotechnology industry.
Lexeo Therapeutics, Inc. entered into an Agreement and Plan of Merger to acquire Mantle Therapeutics Inc., a clinical-stage company focused on Friedreich ataxia therapies. The transaction involves $8.3 million in upfront consideration, comprising $5.3 million in cash and $3.0 million in Lexeo common stock, plus up to $13.0 million in contingent milestone payments over 12 years. Mantle’s portfolio includes clinical-stage LX3010 and preclinical programs LX3030, LX3050, and LX3070 targeting frataxin restoration. Concurrently, Lexeo announced three research collaborations to evaluate cerebellar-targeted sequential dosing of its gene therapy candidate LX2006 with Weill Cornell Medicine, Vivet Therapeutics, and Apertura Gene Therapy. The company confirmed enrollment in the SUNRISE-FA 2 pivotal study for LX2006, targeting cardiomyopathy treatment. Lexeo Therapeutics is a clinical-stage biopharmaceutical company developing genetic disease treatments.
Lexeo Therapeutics reported second quarter 2026 financial results, posting a net loss of $25.9 million or $0.30 per share, compared to a $26.1 million loss in the prior year period. Research and development expenses increased to $19.0 million from $14.7 million, while general and administrative expenses decreased significantly to $9.0 million from $16.0 million. The company ended the quarter with $234.2 million in cash, cash equivalents, and investments, providing an operational runway into 2028. Clinically, Lexeo initiated the SUNRISE-FA 2 pivotal trial for its lead candidate LX2006 in Friedreich ataxia cardiomyopathy, enrolling the first patient in June 2027, with topline data expected in the second half of 2027. Additionally, the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation for LX2020 in PKP2 arrhythmogenic cardiomyopathy based on interim clinical data. Lexeo Therapeutics is a clinical-stage genetic medicine company developing novel treatments for cardiovascular diseases.
Lexeo Therapeutics, Inc. announced regulatory updates for LX2006, its gene therapy candidate for treating Friedreich ataxia (FA) cardiomyopathy, including a pivotal study design intended to support accelerated approval. The company hosted a conference call and webcast to discuss these updates. Lexeo Therapeutics, Inc. is a biotechnology company focused on developing gene therapies for rare diseases.